This database contains 222 studies, archived under the term: "cognition disorders"
Click here to filter this large number of results.
Cognitive subdomain responses to galantamine in Alzheimer’s disease
Song, Jihye,
Ahn, Inn Sook,
Kang, Hyo Shin,
Myung, Woojae,
Lee, Yujin,
Woo, Sook-young,
Ku, Hyoung Mo,
Hwang, Tae-Young,
Carroll, Bernard J.,
Kim, Doh Kwan
We investigated the effects of galantamine on cognitive subdomains in Alzheimer’s disease (AD). Sixty-six patients with mild-to-moderate AD received open-label galantamine for 52 weeks. Cognitive function was measured using the Korean version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog-K). Response to galantamine was defined as “improvement or no deterioration” on the total scores of […]
Assessment of cognition in mild cognitive impairment: a comparative study
Snyder, Peter J.,
Jackson, Colleen E.,
Petersen, Ronald C.,
Khachaturian, Ara S.,
Kaye, Jeffrey,
Albert, Marilyn S.,
Weintraub, Sandra
The demand for rapidly administered, sensitive, and reliable cognitive assessments that are specifically designed for identifying individuals in the earliest stages of cognitive decline (and to measure subtle change over time) has escalated as the emphasis in Alzheimer’s disease clinical research has shifted from clinical diagnosis and treatment toward the goal of developing presymptomatic neuroprotective […]
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene
Snowden, Julie S.,
Hu, Quan,
Rollinson, Sara,
Halliwell, Nicola,
Robinson, Andrew,
Davidson, Yvonne S.,
Momeni, Parastoo,
Baborie, Atik,
Griffiths, Timothy D.,
Jaros, Evelyn,
Perry, Robert H.,
Richardson, Anna,
Pickering-Brown, Stuart M.,
Neary, David,
Mann, David M. A.
Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. Recent descriptions of a pathological sub-type that is ubiquitin positive, TDP-43 negative and immunostains positive for the Fused in Sarcoma protein (FUS) raises the question whether it is associated with a distinct clinical phenotype identifiable on clinical grounds, and whether mutations in the Fused in […]
Effects of age, gender, education and race on two tests of language ability in community-based older adults
Snitz, Beth E.,
Unverzagt, Frederick W.,
Chang, Chung-Chou H.,
Bilt, Joni Vander,
Gao, Sujuan,
Saxton, Judith,
Hall, Kathleen S.,
Ganguli, Mary
Background: Neuropsychological tests, including tests of language ability, are frequently used to differentiate normal from pathological cognitive aging. However, language can be particularly difficult to assess in a standardized manner in cross-cultural studies and in patients from different educational and cultural backgrounds. This study examined the effects of age, gender, education and race on performance […]
25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men
Slinin, Y.,
Paudel, M. L.,
Taylor, B. C.,
Fink, H. A.,
Ishani, A.,
Canales, M. T.,
Yaffe, K.,
Barrett-Connor, E.,
Orwoll, E. S.,
Shikany, J. M.,
LeBlanc, E. S.,
Cauley, J. A.,
Ensrud, K. E.
Objective: To test the hypothesis that lower 25-hydroxyvitamin D [25(OH)D] levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline.; Methods: We measured 25(OH)D and assessed cognitive function using the Modified Mini-Mental State Examination (3MS) and Trail Making Test Part B (Trails B) in a cohort of 1,604 men enrolled […]
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia
Simioni, Samanta,
Cavassini, Matthias,
Annoni, Jean-Marie,
Rimbault Abraham, Aline,
Bourquin, Isabelle,
Schiffer, Véronique,
Calmy, Alexandra,
Chave, Jean-Philippe,
Giacobini, Ezio,
Hirschel, Bernard,
Du Pasquier, Renaud A.
Objective: To determine the prevalence of cognitive complaints and HIV-associated neurocognitive disorders (HANDs) in a cohort of aviremic HIV-positive patients. To evaluate the relevance of the HIV dementia scale to detect HANDs.; Design: Assessment of HANDs with neuropsychological tests.; Methods: Two hundred HIV-infected patients with undetectable HIV-1 RNA concentrations in the plasma, no history of […]
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease
Shinto, Lynne,
Quinn, Joseph,
Montine, Thomas,
Dodge, Hiroko H.,
Woodward, William,
Baldauf-Wagner, Sara,
Waichunas, Dana,
Bumgarner, Lauren,
Bourdette, Dennis,
Silbert, Lisa,
Kaye, Jeffrey
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid […]
A randomized controlled trial of estrogen treatment in men with mild cognitive impairment
This randomized, placebo-controlled, cross-over study investigated whether estrogen treatment would have a beneficial effect on tests of verbal memory in men with mild cognitive impairment (MCI). Forty-three men newly diagnosed with MCI were administered a battery of neuropsychological tests before randomly receiving 12 weeks of treatment with estrogen or placebo followed by a 12 week […]
Relation of hemoglobin to level of cognitive function in older persons
Shah, Raj C.,
Wilson, Robert S.,
Tang, Yuxiao,
Dong, Xinqi,
Murray, Anne,
Bennett, David A.
Background: While decreased hemoglobin concentration is common in the elderly, the relationship of the entire range of hemoglobin concentrations with cognitive function is not well understood.; Methods: Cross-sectional analyses were conducted utilizing data from community-dwelling, older persons participating in the Rush Memory and Aging Project. Proximate to first available hemoglobin measurement, 21 cognitive tests were […]
Cognitive function in early clinical phase huntington disease after rivastigmine treatment
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]